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Abstract One of the newest substances, whose antidepres-
sant activity was shown is traxoprodil, which is a selective
antagonist of the NR2B subunit of the NMDA receptor. The
main goal of the present study was to evaluate the effect of
traxoprodil on animals’ behavior using the forced swim test
(FST), as well as the effect of traxoprodil (10 mg/kg) on the
activity of antidepressants, such as imipramine (15 mg/kg),
fluoxetine (5 mg/kg), escitalopram (2 mg/kg) and reboxetine
(2.5 mg/kg). Serotonergic lesion and experiment using the
selective agonists of serotonin receptors 5-HT1A and 5-HT2
was conducted to evaluate the role of the serotonergic system
in the antidepressant action of traxoprodil. Brain concentra-
tions of tested agents were determined using HPLC. The re-
sults showed that traxoprodil at a dose of 20 and 40 mg/kg
exhibited antidepressant activity in the FST and it was not
related to changes in animals’ locomotor activity. Co-
administration of traxoprodil with imipramine, fluoxetine or
escitalopram, each in subtherapeutic doses, significantly af-
fected the animals’ behavior in the FSTand, what is important,
these changes were not due to the severity of locomotor ac-
tivity. The observed effect of traxoprodil is only partially as-
sociated with serotonergic system and is independent of the
effect on the 5-HT1A and 5-HT2 serotonin receptors. The re-
sults of an attempt to assess the nature of the interaction be-
tween traxoprodil and the tested drugs show that in the case of
joint administration of traxoprodil and fluoxetine, imip-
ramine or escitalopram, there were interactions in the
pharmacokinetic phase.
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Introduction
Glutamate (Glu) is one of the most important and present in
the highest concentration excitatory amino acid neurotrans-
mitter in the central nervous system (CNS) (McGeer et al.
1987). Glutamatergic system has the greatest diversity of both
construction and function of receptors compared with other
CNS neurotransmitter systems. Glutamate ionotropic recep-
tors have been identified as the first ones and, in the 80s, the
first scientific evidence onmetabotropic receptors was provid-
ed (Nicoletti et al. 1986). One of the ionotropic glutamate
receptors is NMDA receptor, which is stimulated by N-meth-
yl-D-aspartic acid (NMDA) (Glasgow et al. 2015; Machado-
Vieira et al. 2010; Traynelis et al. 2010).
In the 1990s the first studies showing the antidepressant-like
effect of compounds that are antagonists of NMDA receptors
were carried out (Trullas and Skolnick 1990). Nowadays,
there are a number of pre-clinical and clinical reports which
have shown the antidepressant potential of the NMDA recep-
tor antagonists, as well as their influence on the effectiveness
of the antidepressant drugs (Cichy et al. 2009; Dybała et al.
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2008; Heresco-Levy et al. 2006; Muhonen et al. 2008;
Poleszak et al. 2008; Preskorn et al. 2008; Skolnick et al.
2009; Sowa-Kućma et al. 2011; Szewczyk et al. 2009,
2010; Zarate et al. 2006). Therefore, inhibition of the
NMDA receptor complex may provide new possibilities in
the treatment of mental disorders (e.g., DiazGranados et al.
2010; Gosek et al. 2012; Maeng and Zarate 2007; Poleszak
et al. 2014; Price et al. 2009).
The role of NR2B subunit of the NMDA receptor has been
demonstrated in the action of different antidepressant agents
(Layer et al. 1995; Li et al. 2011; Maeng et al. 2008; Poleszak
et al. 2013, 2014; Preskorn et al. 2008). A number of clinical
studies have confirmed the remarkable antidepressant effects
produced by the NMDA antagonist – traxoprodil (CP-101,
606) (Preskorn et al. 2008; Skolnick et al. 2009; Zarate et al.
2006). Traxoprodil is a selective antagonist of the NR2B sub-
unit of the NMDA receptor (Chenard et al. 1995). It antago-
nizes the activity of the NR1/NR2B channel by shortening the
time and frequency of its opening. As a result, it prevents a
damaging influx of calcium ions into the neurons caused by
the release of large quantities of glutamate from the damaged
tissue (Kundrotiene et al. 2004; Mony et al. 2009).
Traxoprodil binding site is mainly located in forebrain, hippo-
campus and the outer layers of cortex (Menniti et al. 1997).
This agent appeared to be safe and generally well-tolerated,
capable of producing an antidepressant response in patients
with treatment-refractory major depressive disorders
(Preskorn et al. 2008).
The main goal of this study was to assess the effect of
traxoprodil on animals’ behavior using the forced swim test
(FST) in mice. Moreover, we also decided to evaluate the
influence of traxoprodil at the inactive dose on the activity
of the commonly used antidepressants, i.e., imipramine – a
tricyclic antidepressant (TCA), fluoxetine, escitalopram – a
selective serotonin reuptake inhibitor (SSRI), and reboxetine
– a selective noradrenaline reuptake inhibitor (SNRI). In order
to evaluate the role of the serotonergic system in the antide-
pressant potential of traxoprodil, we subjected the mice to
serotonergic lesion with p-chlorophenylalanine (p-CPA). In
order to elucidate the role of serotonin receptors 5-HT1A and
5-HT2 in the operation of traxoprodil, we conducted experi-
ment using the selective agonists of these receptors – WAY
100,635 and ritanserin, respectively.
Materials and methods
Animals
The experiments were carried out on naïve adult male Albino
Swiss mice (25–30 g) purchased from the licensed breeder
(Kołacz, Warsaw, Poland). The animals were housed in the
environmentally controlled rooms with a 12 h light/dark cycle,
in groups of 10 in standard cages under strictly controlled
laboratory conditions – temperature maintained at 22–23 °C,
relative humidity about 45–55 %. Throughout the study, the
animals were given ad libitum access to water and food. The
experiments began after at least 1-week acclimation period in
the laboratory conditions and were conducted between 8 a.m.
and 3 p.m. to minimize circadian influence. Each experimen-
tal group consisted of 8–10 animals. All procedures were con-
ducted in accordance with the European Communities
Council Directive of 22 September 2010 (2010/63/EU) and
Polish legislation acts concerning animal experimentations.
The experimental procedures and protocols were approved
by the First Local Ethics Committee at the Medical
University of Lublin (license no 33/2013). Each mouse was
used only once.
Drug administration
Traxoprodil (5, 10, 20, and 40 mg/kg, Sigma-Aldrich) was
suspended in a 1 % aqueous solution of Tween 80 (POCH),
whereas imipramine hydrochloride (15 and 30 mg/kg, Sigma-
Aldrich), fluoxetine hydrochloride (5 mg/kg, Sigma-Aldrich),
escitalopram oxalate (2 mg/kg, Sigma-Aldrich), reboxetine
mesylate (2.5 mg/kg, Abcam Biochemicals), WAY 100,635
(0.1 mg/kg, Sigma-Aldrich), and ritanserin (4 mg/kg, Sigma-
Aldrich) were dissolved in physiological saline (0.9 % NaCl).
The solutions/suspension were prepared immediately prior to
the experiments and were administered intraperitoneally (i.p.)
60 min before testing. The doses and pretreatment schedules
were selected on the basis of the literature data and the results
of our previous experiments (Poleszak et al. 2005, 2007a,
2011, 2013; Szewczyk et al. 2002, 2009). Animals from the
control groups received i.p. injections of the vehicle (saline).
The volume of all administered solutions/suspension was
10 ml/kg.
Serotonergic lesion
p-CPAwas dissolved in saline and administered i.p. at a dose
of 200 mg/kg for 3 consecutive days. Mice from the control
group received i.p. injections of saline. On the fourth day, the
animals were given traxoprodil at an active dose (20mg/kg) or
saline, and 60 min later, the FST and locomotor activity tests
were performed.
Forced swim test (FST)
The procedure was carried out onmice, according to the meth-
od of Porsolt et al. (1977). Each mouse was placed individu-
ally into a glass cylinder (height 25 cm, diameter 10 cm) con-
taining 12–15 cm of water at 23–25 °C. The animal was left in
the cylinder for 6 min. The total duration of immobility was
recorded during the last 4 min of the 6-min testing period. The
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mouse was judged to be immobile when it ceased struggling
and remained floating motionless in the water, making only
the movements necessary to keep its head above the water
level.
The results obtained in the FSTwere shown as an arithmet-
ic mean of immobility time of animals (given in seconds) ±
standard error of the mean (SEM) for each experimental
group.
Spontaneous locomotor activity
In order to avoid the risk of obtaining the false positive/
negative effects in the FST caused by a possible influence of
the tested drugs on the locomotor activity, spontaneous loco-
motor activity was measured using an animal activity meter
Opto-Varimex-4 Auto-Track (Columbus Instruments, USA).
The device consists of four transparent cages with a lid
(43×43×32 cm), a set of four infrared emitters (each emitter
has 16 laser beams), and four detectors monitoring animal
movements. Each mouse was placed individually into the
cage for 10 min. Spontaneous locomotor activity was evalu-
ated between the 2nd and the 6th min, which corresponds with
the time interval analyzed in the FST.
The results obtained in this test were presented as an arith-
metic average distance (given in cm) traveled by a mouse ±
SEM for each experimental group.
Determination of antidepressants and traxoprodil
in brains
Sixty minutes following administration of studied antidepres-
sant drugs with or without traxoprodil, mice were decapitated
to collect brains for pharmacokinetic studies. Immediately af-
ter the decapitation, the brains were dissected from the skull,
washed with 0.9 % NaCl and frozen at −25 °C.
Brain concentrations of the studied antidepressants and
traxoprodil were assayed by high performance liquid chroma-
tography (HPLC) methods. The brains were homogenized in
distilled water (1 : 4, w/v) with a tissue homogenizer TH220
(Omni International, Inc., Warrenton, VA, USA). For all stud-
ied antidepressant drugs, the extraction from brain homoge-
nates were performed using the mixture of ethyl acetate :
hexane (30 : 70, v/v). Amitriptyline (2 μg/ml) was used as
an internal standard (IS) for imipramine and paroxetine
(200 ng/ml) for fluoxetine and escitalopram. In order to isolate
imipramine and its metabolite desipramine, to brain homoge-
nate (0.5 ml) containing these drugs the IS was added and the
samples were alkalized with 250 μl of 4 M NaOH. Then the
samples were extracted with 5 ml of the extraction reagent by
shaking for 20 min (IKAVibrax VXR, Germany). After cen-
trifugation at 3000 rpm for 20 min (Universal 32, Hettich,
Germany), the organic layer was transferred to a new tube
containing a 200 μl solution of 0.1 M H2SO4 and methanol
(90 : 10, v/v), shaken for 0.5 h and then centrifuged for 15 min
(3000 rpm). The organic layer was discarded and a 50 μl
aliquot of the acidic solution was injected into the HPLC sys-
tem. In the case of escitalopram, the procedure was similar
with the exception that the extraction with an organic reagent
was repeated two times, 1 ml of brain homogenate was used,
and the volume of the acidic phase was 100 μl. In turn, to 1 ml
of brain homogenates containing fluoxetine the IS was added
and the samples were alkalized with 500 μl of 4 M NaOH.
After the addition of 1 ml of the concentrated NaCl solution
(10 g/50 ml), the samples were vortexed for 15 s and 5 ml of
the extraction reagent was added. Then the samples were
shaken for 20 min and centrifuged for 15 min at 3000 rpm.
After the centrifugation, the organic layer was transferred into
a conical glass tube and evaporated to dryness at 37 °C under a
gentle stream of nitrogen in a water bath. The residue was
dissolved with 100 μl of methanol and 50 μl of this solution
was injected into the HPLC system.
The HPLC system (Thermo Separation Products, San Jose,
CA, USA) consisted of a P100 isocratic pump, a UV100
variable-wavelength UV/VIS detector, a Rheodyne 7125 in-
jector (Rheodyne, Cotati, CA, USA) with a 50μl sample loop,
and a Chromjet SP4400 computing integrator.
All analyses were performed on a 250 × 4.0 mm
LiChrospher®100 RP-18 column with a particle size of
5 μm (Merck, Darmstadt, Germany) protected with a guard
column (4×4 mm) with the same packing material. The mo-
bile phase consisting of 50 mM potassium dihydrogen phos-
phate buffer (pH=4.5) and acetonitrile was mixed at a ratio of
60 : 40 (v/v) for imipramine and fluoxetine, and 65 : 35 (v/v)
for escitalopram and run at 1 ml/min. Chromatographic anal-
ysis was carried out at 21 °C and the analytical wavelength of
227 nm for fluoxetine, 240 nm for escitalopram, and 214 nm
for imipramine.
In order to determine traxoprodil concentrations in mice
brain, to 1 ml of brain homogenate containing this compound
2 ml of methanol was added and the samples were briefly
vortexed and then shaken vigorously for 10 min (IKA
Vibrax VXR, Germany) to precipitate proteins. After centri-
fugation for 20 min at 3000 rpm the supernatant (2 ml) was
transferred into a conical glass tube and evaporated to dryness
at 45 °C under a gentle stream of nitrogen in a water bath. The
residue was dissolved with 100 μl of methanol and 40 μl of
this solution were injected into the HPLC system.
The HPLC system (Merck-Hitachi LaChrom Elite)
consisted of an L-2130 pump, an L-2200 autosampler, an
L-2350 column oven, and an L-2485 fluorescence detector.
EZChrome Elite v. 3.2 (Merck Hitachi) software was used for
data acquisition. The analysis was performed on a
250 × 4.0 mm LiChrospher®100 RP-18 column (Merck,
Darmstadt, Germany) maintained at 30 °C, protected with a
guard-column (4×4 mm) of the same material. The mobile
phase consisted of 50 mM potassium dihydrogen phosphate
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buffer, pH 4.5 : acetonitrile : methanol (70:20:10, v/v/v). The
flow rate was 1.0 ml/min and the fluorescence detector was set
at an excitation wavelength of 200 nm and an emission
wavelength of 300 nm.
The calibration curves constructed by plotting the ratio of
the peak heights of the studied drug to IS (or peak area for
traxoprodil) versus concentration of the drug were linear in the
tested concentration ranges. No interfering peaks were ob-
served in the chromatograms. The assays were reproducible
with low intra- and inter-day variation (coefficient of variation
less than 10 %). The extraction efficiencies of the analyzed
compounds and internal standards ranged from 66 to 97 %.
Concentrations of antidepressants and traxoprodil were
expressed in ng/g of wet brain tissue.
Statistical analysis
The statistical analysis of the results obtained in the FST and
the locomotor activity assessment following traxoprodil ad-
ministration was carried out using one-way ANOVA with
Dunnett’s post hoc test and after joint treatments using two-
way ANOVAwith Bonferroni’s post hoc test. The concentra-
tions of the tested antidepressant drugs in murine brains in the
presence and absence of traxoprodil were compared using
Student’s t-test. P values less than or equal to 0.05 were con-
sidered statistically significant.
Results
Forced swim test (FST)
Traxoprodil dose-effect relationship in FST
In order to determine an antidepressant activity of traxoprodil,
it was used at doses of 5, 10, 20, and 40 mg/kg (Fig. 1).
Statistical analysis of the results obtained in the FST showed
that traxoprodil used at doses of 5 and 10 mg/kg had no
statistically significant effect (p>0.05) on the reduction of
the immobility time in mice. However, traxoprodil adminis-
tered at a dose of 20 and 40 mg/kg significantly reduced the
total time of immobility in comparison with the control group
[one-way ANOVA: F(5,42)=26.41; p<0.0001].
Effect of combined administration of traxoprodil
and imipramine in FST
The effect of the combined administration of traxoprodil and
imipramine on total duration of the immobility time in mice is
shown in Fig. 2a. Traxoprodil (10 mg/kg) injected in combi-
nation with imipramine (15 mg/kg) significantly reduced the
immobility time in the FST in mice (Fig. 2a). Imipramine
(15 mg/kg) and traxoprodil (10 mg/kg) given alone had no
effect on the immobility time (Fig. 2a).
Two-way ANOVA demonstrated a significant effect of
traxoprodil [F(1,28)=26.08; p<0.0001], a significant effect
of imipramine [F(1,28)=27.44; p<0.0001], and a significant
interaction between imipramine and traxoprodil [F(1,
28)=32.99; p<0.0001].
Effect of combined administration of traxoprodil
and fluoxetine in FST
The effect of the combined administration of traxoprodil and
fluoxetine on total duration of the immobility time in mice is
shown in Fig. 2b. Traxoprodil (10 mg/kg) injected in combi-
nation with fluoxetine (5 mg/kg) significantly reduced the
immobility time in the FST in mice (Fig. 2b). Fluoxetine
(5 mg/kg) and traxoprodil (10 mg/kg) given alone had no
effect on the immobility time (Fig. 2b).
Two-way ANOVA demonstrated no effect of traxoprodil
[F(1,28)=1.05; p=0.3151], a significant effect of fluoxetine
[F(1,28) = 7.46; p = 0.0108], and no interaction between
fluoxetine and traxoprodil [F(1,28)=3.15; p=0.0870].
Effect of combined administration of traxoprodil
and escitalopram in FST
The effect of the combined administration of traxoprodil and
escitalopram on total duration of the immobility time in mice
is shown in Fig. 2c. Traxoprodil (10 mg/kg) injected in com-
bination with escitalopram (2mg/kg) significantly reduced the
immobility time in the FST in mice (Fig. 2c). Escitalopram
(2 mg/kg) and traxoprodil (10 mg/kg) given alone had no
effect on the immobility time (Fig. 2c).
Two-way ANOVA demonstrated a significant effect of
traxoprodil [F(1,28)=22.79; p<0.0001], a significant effect of
escitalopram [F(1,28)=34.90; p<0.0001], and a significant in-
teraction between escitalopram and traxoprodil [F(1,28)=33.27;
p<0.0001].
Fig. 1 The antidepressant activity of traxoprodil in the FST in mice.
Traxoprodil, imipramine and saline were administered i.p. 60 min
before the test. The data are presented as the means + SEM. Each
experimental group consisted of 8 animals. ***p < 0.001 (one-way
ANOVA followed by Dunnett’s post hoc test)
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Effect of combined administration of traxoprodil
and reboxetine in FST
The effect of the combined administration of traxoprodil and
reboxetine on total duration of the immobility time in mice is
shown in Fig. 2d. Traxoprodil (10 mg/kg) injected in combi-
nation with reboxetine (2.5 mg/kg) did not reduce the immo-
bility time in the FST in mice (Fig. 2d). Reboxetine
(2.5 mg/kg) and traxoprodil (10 mg/kg) given alone had no
effect on the immobility time (Fig. 2d).
Two-way ANOVA demonstrated no effect of traxoprodil
[F(1,28) = 0.02; p= 0.8827], no effect of reboxetine [F(1,
28)=1.09; p=0.3061], and no interaction between reboxetine
and traxoprodil [F(1,28)=0.53; p=0.4746].
Influence of serotonergic lesion on antidepressant-like activity
of traxoprodil in FST
The effect of the combined administration of traxoprodil and
p-CPA on total duration of the immobility time in mice is
shown in Fig. 3a. Traxoprodil (20 mg/kg) significantly re-
duced the immobility time in the FST in mice (Fig. 3a). p-
CPA (200mg/kg administered per 3 days) had no effect on the
immobility time (Fig. 3a). Traxoprodil (20 mg/kg) injected in
combination with p-CPA (200mg/kg administered per 3 days)
partially reversed the antidepressant-like effect of traxoprodil
in the FST in mice (Fig. 3a).
Two-way ANOVA demonstrated a significant effect of
traxoprodil [F(1,28)=66.37; p<0.0001], a significant effect
of p-CPA [F(1,28)=7.80; p=0.0093], and a significant inter-
action between p-CPA and traxoprodil [F(1,28) = 12.95;
p=0.0012].
Influence of WAY 100,635 on antidepressant-like activity
of traxoprodil in FST
The effect of the combined administration of traxoprodil
and WAY 100,635 on total duration of the immobility time
in mice is shown in Fig. 3b. Traxoprodil (20 mg/kg) sig-
nificantly reduced the immobility time in the FST in mice
(Fig. 3b). WAY 100,635 (0.1 mg/kg) had no effect on the
immobility time (Fig. 3b). Traxoprodil (20 mg/kg) injected
in combination with WAY 100,635 (0.1 mg/kg) did not
reverse the antidepressant-like effect of traxoprodil
(20 mg/kg) in the FST in mice versus group receiving
traxoprodil, but significantly reduced the immobility time
versus group receiving WAY 100,635 (0.1 mg/kg)
(Fig. 3b).
Two-way ANOVA demonstrated a significant effect of
traxoprodil [F(1,27)=26.49; p<0.0001], no effect of WAY
100,635 [F(1,27)=0.08; p=0.7745], and no interaction be-
tween WAY 100,635 and traxoprodil [F(1,27) = 1.66;
p=0.2087].
Fig. 2 Effect of combined
administration of traxoprodil and
antidepressants in the FST in
mice. Antidepressants,
traxoprodil and saline were
administered i.p. 60 min before
the test. The values represent
mean + SEM (n= 10 per group).
**p< 0.01; ***p< 0.001 (two-
way ANOVA followed by
Bonferroni’s post hoc test)
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Influence of ritanserin on antidepressant-like activity
of traxoprodil in FST
The effect of the combined administration of traxoprodil and
ritanserin on total duration of the immobility time in mice is
shown in Fig. 3c. Traxoprodil (20 mg/kg) significantly re-
duced the immobility time in the FST in mice (Fig. 3c).
Ritanserin (4 mg/kg) had no effect on the immobility time
(Fig. 3c). Traxoprodil (20 mg/kg) injected in combination
with ritanserin (4 mg/kg) did not reverse the antidepressant-
like effect of traxoprodil (20 mg/kg) in the FST in mice versus
group receiving traxoprodil, but significantly reduced the im-
mobility time versus group receiving ritanserin (4 mg/kg)
(Fig. 3c).
Two-way ANOVA demonstrated a significant effect of
traxoprodil [F(1,27) = 33.67; p < 0.0001], no effect of
ritanserin [F(1,27)=0.50; p=0.4864], and no interaction be-
tween ritanserin and traxoprodil [F(1,27)=0.36; p=0.5555].
Spontaneous locomotor activity
Effect of traxoprodil on locomotor activity in mice
The effect of traxoprodil (5, 10, 20, and 40 mg/kg) on spon-
taneous locomotor activity in mice is shown in Table 1.
Statistical analysis of the results showed that traxoprodil used
in all tested doses had no statistically significant effect on
locomotor activity in mice versus control group [one-way
ANOVA: F(5,42)=1.661; p=0.1653].
Effect of combined administration of traxoprodil
and antidepressants on locomotor activity in mice
The effect of the combined administration of traxoprodil and
tested antidepressant drugs on spontaneous locomotor activity
in mice is shown in Table 2.
Traxoprodil (10 and 20 mg/kg), antidepressants (imipra-
mine, fluoxetine, escitalopram, and reboxetine), or p-CPA,
WAY 100,635 and ritanserin administered either alone or
combined together had no statistically significant effects on
locomotor activity in mice (Table 2).
Two-way ANOVA demonstrated:
(A): no effect of imipramine [F(1,26)=2.72; p=0.1112], no
effect of traxoprodil [F(1,26)=032; p=0.5752], and no
interaction [F(1,26)=3.23; p=0.0840].Fig. 3 Effect of combined administration of traxoprodil and p-CPA and
selective agonists of serotonin receptors 5-HT1A and 5-HT2 in the FST in
mice. Traxoprodil, WAY 100635, ritanserin and saline were administered
i.p. 60 min before the test. p-CPAwas administered i.p. once per day over
three consecutive days. The values represent mean + SEM (n= 10 per
group). *p < 0.05; **p < 0.01; ***p < 0.001 (two-way ANOVA
followed by Bonferroni’s post hoc test)
Table 1 Effect of traxoprodil on locomotor activity in mice
Treatment (mg/kg) Distance traveled (cm)
saline (control group) 1014 ± 151.8
traxoprodil 5 915.0 ± 92.10
traxoprodil 10 738.5 ± 49.93
traxoprodil 20 912.0 ± 75.87
traxoprodil 40 789.1 ± 119.8
imipramine 30 653.9 ± 99.38
Traxoprodil, imipramine and saline were administered i.p. 60 min before
the test. Distance traveled was recorded between the 2nd and the 6th min of
the test. The data are presented as the means ± SEM. Each experimental
group consisted of 8 animals. The results were considered statistically sig-
nificant if p<0.05 (one-way ANOVA followed by Dunnett’s post hoc test)
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(B): no effect of fluoxetine [F(1,27)=0.12; p=0.7289], no
effect of traxoprodil [F(1,27)=0.01; p=0.9320], and no
interaction [F(1,27)=0.59; p=0.4473].
(C): no effect of escitalopram [F(1,28)=0.51; p=0.4817],
no effect of traxoprodil [F(1,28) = 0.78; p= 0.3855],
and no interaction [F(1,28)=0.01; p=0.9273].
(D): no effect of reboxetine [F(1,27)=0.79; p=0.3825], no
effect of traxoprodil [F(1,27) =0.01; p=0.9681], and
no interaction [F(1,27)=0.96; p=0.3357].
(E): no effect of p-CPA [F(1,28)=1.33; p=0.2579], no ef-
fect of traxoprodil [F(1,28)=0.42; p=0.5205], and no
interaction [F(1,28)=1.11; p=0.3014].
(F): no effect of WAY 100,635 [F(1,28)=3.96; p=0.0563],
no effect of traxoprodil [F(1,28)=1.47; p=0.2351], and
no interaction [F(1,28)=0.71; p=0.4076].
(G): no effect of ritanserin [F(1,28)=6.17; p=0.0193], no
effect of traxoprodil [F(1,28) =1.70; p=0.2030], and
no interaction [F(1,28)=0.34; p=0.5624].
Pharmacokinetic studies
The effect of traxoprodil on brain concentrations of the tested
antidepressants in mice is shown in Table 3. A significant
increase in concentrations of imipramine, its metabolite (de-
sipramine), and escitalopram in brain tissue after joint admin-
istration with traxoprodil were noticed (t-test: p < 0.05,
p < 0.001, and p < 0.05, respectively). In the case of co-
administration of traxoprodil and fluoxetine no significant
changes in fluoxetine concentration in brain were observed
(t-test: p>0.05) (Table 3).
The effect of tested drugs on brain concentration of
traxoprodil in mice is shown in Table 4. In the case of joint
administration of traxoprodil and fluoxetine or escitalopram a
significant increase in traxoprodil concentration in brain was
noted (t-test: p<0.001 and p<0.01, respectively). No statisti-
cally significant changes in concentration of traxoprodil were
obtained in the group treated with traxoprodil and imipramine
vs the traxoprodil group (t-test: p>0.05).
Discussion
To our knowledge, this is the first study to demonstrate inter-
actions between traxoprodil and antidepressant drugs acting
Table 2 Effect of treatments on spontaneous locomotor activity inmice
Treatment (mg/kg) Distance traveled
(cm)
(A) saline + saline 705.0 ± 39.07
traxoprodil 10 + saline 629.1 ± 79.29
imipramine 15 + saline 492.3 ± 57.11
traxoprodil 10 + imipramine 15 638.3 ± 57.77
(B) saline + saline 705.0 ± 39.07
traxoprodil 10 + saline 629.1 ± 79.29
fluoxetine 5 + saline 667.8 ± 111.1
traxoprodil 10 + fluoxetine 5 728.4 ± 96.91
(C) saline + saline 815.6 ± 63.98
traxoprodil 10 + saline 986.8 ± 278.5
escitalopram 2 + saline 957.1 ± 174.1
traxoprodil 10 + escitalopram 2 1096± 107.6
(D) saline + saline 705.0 ± 39.07
traxoprodil 10 + saline 629.1 ± 79.29
reboxetine 2.5 + saline 566.1 ± 54.75
traxoprodil 10 + reboxetine 2.5 636.0 ± 100.8
(E) saline + saline 983.8 ± 224.3
traxoprodil 20 + saline 731.1 ± 145.1
p-CPA 200 + saline 656.4 ± 107.4
traxoprodil 20 + p-CPA 200 716.0 ± 70.99
(F) saline + saline 815.6 ± 63.98
traxoprodil 20 + saline 687.5 ± 71.45
WAY 0.1 + saline 639.0 ± 59.16
traxoprodil 20 + WAY 0.1 615.8 ± 53.48
(G) saline + saline 815.6 ± 63.98
traxoprodil 20 + saline 687.5 ± 71.45
ritanserin 4 + saline 607.5 ± 79.78
traxoprodil 20 + ritanserin 4 558.9 ± 53.11
Antidepressants, traxoprodil and saline were administered i.p. 60 min
before the experiment. p-CPAwas administered i.p. once daily over three
consecutive days. Distance traveled was recorded between the 2nd and
the 6th min of the test. Each experimental group consisted of 8 animals.
Data are presented as the means ± SEM. The results were considered
statistically significant if p < 0.05 (two-way ANOVA followed by
Bonferoni’s post hoc test)





(A) imipramine 15 + saline 2065± 252.6
(metabolite – desipramine) (101.0 ± 19.86)
imipramine 15 + traxoprodil 10 3207± 373.8*
(metabolite – desipramine) (724.0 ± 109.0***)
(B) fluoxetine 5 + saline 4835± 382.8
fluoxetine 5 + traxoprodil 10 5122± 261.8
(C) escitalopram 2 + saline 295.5 ± 17.68
escitalopram 2 + traxoprodil 10 360.9 ± 20.46*
Antidepressants and traxoprodil were administered i.p. 60 min before
decapitation. Each experimental group consisted of 10 animals. Results
are presented as mean values ± SEM. *p < 0,05; ***p < 0.001 compared
with the respective control group (Student’s t-test)
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via the monoamine transduction given at non-effective doses
in the FST in mice.
The antidepressant activity of the NMDA receptor antago-
nists has been revealed inmany tests and depressionmodels. It
was proved that competitive NMDA receptor antagonists
(AP7, CGP 37849), zinc ligands (Zn2+), polyamine ligands
(eliprodil, ifenprodil), phencyclidine ligands (memantine,
MK-801) and glycine ligands (ACPC, 7- chlorokynurenic ac-
id) show antidepressant-like activity in a forced swim test
(Cichy et al. 2009; Dybała et al. 2006, 2008; Ossowska
et al. 1997; Papp and Moryl 1994; Poleszak et al. 2007b,
2008; Redmond et al. 1997; Sowa-Kućma et al. 2008;
Szewczyk et al. 2001, 2006, 2008, 2009, 2010). It should be
noted that the observed effect was comparable with that of
tricyclic antidepressants. In animal studies, it was observed
that the abrupt withdrawal of imipramine entails a rapid and
significant increase in glutamatergic transmission (Skolnick
et al. 1996). It was also found that a variety of ligands that
modulate the NMDA complex enhance the effects of antide-
pressant drugs such as imipramine, citalopram or fluoxetine
(Cieślik et al. 2007; Poleszak et al. 2011, 2014; Szewczyk
et al. 2002).
One of the newest substances, whose antidepressant activ-
ity was shown is CP-101,606 (traxoprodil) (Chazot et al.
2002; Chenard et al. 1995; Menniti et al. 2000). Traxoprodil
is an NMDA receptor antagonist with a strong affinity for the
NR2B subunit of this receptor (Guscott et al. 2003; Loftis and
Janowsky 2003; Menniti et al. 1997, 2000). It is an analogue
of ifenprodil, but devoid of activity against α1- adrenergic
receptors, which eliminates the side effects. By modulating
the proton (Dingledine et al. 1999; Guscott et al. 2003; Mott
et al. 1998) and allosteric regulation (Mony et al. 2009)
traxoprodil inhibits NMDA receptor activity. Traxoprodil, by
inhibition of channel activity of subunits NR1/NR2B, reduces
the time and the frequency of its opening, thus preventing the
excessive influx of calcium ions into neurons, and their dam-
age, and consequently the release of large amounts of glutamic
acid (Brimecombe et al. 1998; Chenard et al. 1995).
Recently encouraging results brought the research on ap-
plying traxoprodil in the treatment of depression. Its antide-
pressant effect was similar to that of ketamine, and it brought a
bigger relief in depressive manifestations compared with pla-
cebo, and a fast improvement in the condition of patients not
responding to treatment with SSRIs (Preskorn et al. 2008). In
the present study, the antidepressant-like effect of traxoprodil
in the FST in mice has been shown. The obtained results
demonstrated that a 20 and 40 mg/kg dose of traxoprodil are
sufficient to obtain a statistically significant reduction in the
immobility time of animals in carried out behavioral tests. The
results are consistent with our previous study on ifenprodil
(Poleszak et al. 2013, 2014), which selectively binds to the
NR1/NR2B receptor subtype (Williams 2009). We demon-
strated that ifenprodil has an antidepressant effect in the FST
at the same dose range (20–40 mg/kg) (Poleszak et al. 2013).
Shortening the duration of immobility observed in both stud-
ies using traxoprodil and ifenprodil was not associated with
the increase of spontaneous locomotor activity (Poleszak et al.
2013). Moreover, the highest dose used by us exerted an effect
similar to the action of imipramine administered at an active
dose (30 mg/kg). Based on the dose-effect examination, the
dose of traxoprodil for further testing was selected.
Recent studies indicate that ifenprodil co-administered
with antidepressant agents with distinct pharmacological pro-
files, each given at ineffective doses, produced a significant
antidepressant-like effect in the FST (Ghasemi et al. 2009;
Poleszak et al. 2014). A similar effect on the duration of the
immobility time was observed in animal studies in which low
doses of other NMDA receptor antagonists were administered
concomitantly with antidepressants in the following groups:
TCA – imipramine, SSRI – fluoxetine, SNRI – reboxetine,
and a selective serotonin reuptake enhancer (SSRE) –
tianeptine (Maj et al. 1992a, b; Poleszak et al. 2011, 2013,
2014) (Pruus et al. 2010; Rogóż et al. 2002, 2004).
After the first experiment with imipramine (15 mg/kg), the
obtained results suggested that traxoprodil may intensify ac-
tivity of antidepressant drugs whose mechanism of action is
related to the effects of both serotonergic and noradrenergic
transduction. Therefore, in the subsequent stages of research,
the effect of traxoprodil on the action of antidepressant drugs
which affect selectively particular neurotransmitter systems
has been determined. From SSRIs, fluoxetine (5 mg/kg) and
escitalopram (2 mg/kg) have been selected for examination.
Reboxetine (2.5 mg/kg) has been chosen as a representative of
the SNRIs group. Traxoprodil did not affect the antidepressant
activity of reboxetine, but potentiated the effect of all used
SSRIs. The target point of action of reboxetine is pre- and
postsynaptic adrenergic receptors (Hajos et al. 2004). Its
mechanism of action is associated with the selective inhibition
of the norepinephrine transporters (NET), which leads to an
increased availability of noradrenalin (NA) around synaptic
slots (Eyding et al. 2010). No effect of traxoprodil on the





traxoprodil 10 + saline 76.40 ± 13.51
(A) traxoprodil 10 + imipramine 15 119.2 ± 22.52
(B) traxoprodil 10 + fluoxetine 5 150.6 ± 10.34***
(C) traxoprodil 10 + escitalopram 2 248.9 ± 49.25**
Antidepressants and traxoprodil were administered ip 60 min before de-
capitation. Each experimental group consisted of 7–8 animals. Results are
presented as mean values ± SEM. **p < 0.01; ***p < 0.001 compared
with the control group (Student’s t-test)
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antidepressant action of reboxetine may stem from its mecha-
nism of action, and may suggest no impact of NR2B subunit
of NMDA receptors on the functioning of the noradrenergic
system. Shortening of the immobility time in the FST in mice,
thus the synergism of the antidepressant action, was not ob-
served in research conducted in the same scheme using a
concomitant administration of reboxetine and ifenprodil at
ineffective doses (Poleszak et al. 2014). It should be noticed,
that in the literature there are reports indicating a lack of clin-
ical efficacy of reboxetine (Eyding et al. 2010), which can also
explain the absence of synergism between traxoprodil and
reboxetine.
The mechanism of antidepressant action of SSRIs is asso-
ciated with selective activity at the rise of the serotonergic
system in the CNS by inhibiting the reuptake of serotonin
(5-HT). This mechanism, because of its highly selective na-
ture, helps exclude the direct influence of other neurotransmit-
ters, such as NA or dopamine (DA). When it comes to fluox-
etine, the fact that it is considered as a selective inhibitor of the
NMDA receptor subunit GluN2B could be important (Kiss
et al. 2012). The effect of traxoprodil on the antidepressant-
like action was marked the strongest for escitalopram, which
is the most selective compound of the currently available
SSRIs (Montgomery et al. 2001). It is worth remembering that
behavioral effects observed in the FST were not associated
with the increase in spontaneous locomotor activity of ani-
mals. The results obtained in these studies are in line with
ongoing research of other authors who have shown the direct
interaction between the glutamatergic and serotonergic sys-
tems. It has been demonstrated that as a result of the NMDA
receptor inhibition increasing the level of 5-HT in CNS neu-
rons was observed (Löscher et al. 1993). Furthermore, non-
competitive NMDA receptor antagonists (phencyclidine and
MK-801) also enhance the serotonin level in the CNS (Martin
et al. 1997; Yan et al. 1997). The synergistic interactions be-
tween some NMDA antagonists and the antidepressant drugs
whose mechanism of action is associated with serotonergic
transduction (Maj et al. 1992a, b; Poleszak et al. 2005,
2007b, 2014; Szewczyk et al. 2002, 2009), and no such inter-
action in the case of drugs that act selectively on noradrenergic
transduction (reboxetine) were noticed (e.g., Poleszak et al.
2007b; Pontieri et al. 1995; Szewczyk et al. 2009).
In order to verify the role of the serotonergic system in the
antidepressant-like effect of traxoprodil, serotonergic lesion
was performed. A 3-day-long administration of p-chloro- phe-
nylalanine (p-CPA), a compound inhibiting the activity of
tryptophan hydroxylase (an enzyme that plays a key role in
the biosynthesis of 5-HT in CNS neurons) (O’Leary et al.
2007), did not change the activity of animals in the FST.
However, a partial reduction of antidepressant action of
traxoprodil (20 mg/kg) was demonstrated. This indicates only
the partial participation of the serotonergic system in the anti-
depressant activity of this agent. The obtained results are not
entirely consistent with other authors’ outcomes which
showed that the blockade of serotonergic system by p-CPA
revoke the effect of antidepressant action of other ligands that
modulate the NMDA receptor, such as Mg2+, Zn2+ or D-cy-
closerine (Poleszak et al. 2007b, 2011; Szewczyk et al. 2009).
The demonstration of a partial role of serotonergic neuro-
transmission in the action of traxoprodil became the reason to
continue studies aimed at clarification of the role of different
subtypes of serotonin receptors in its antidepressant effect.
Literature data indicate that in the course of affective disorders
an increase in sensitivity of 5-HT2A receptors and desensitiza-
tion of 5-HT1A are observed (Stahl 1994). What is more, some
researchers believe that lowering the sensitivity of 5-HT1A
receptors is the primary mechanism underlying dysfunction
of serotonergic system in major depressive disorder (Cowen
2000). The evidence of this hypothesis may be the fact that
during the administration of antidepressants, the sensitivity of
5-HT1A receptors significantly increased (Hensler 2003;
Savitz et al. 2009). Therefore, the impact of WAY 100,635
(selective antagonist of the 5-HT1A) and ritanserin (selective
antagonist of the 5-HT2A/2C) (Akhondzadeh et al. 2008; Nappi
et al. 1990) on the antidepressant activity of traxoprodil in the
FST in mice was examined. The results showed that WAY
100,635 and ritanserin applied at a dose of 0.1 and 4 mg/kg,
respectively, did not affect the antidepressant activity of
traxoprodil (20 mg/kg). It should be noticed that, in the case
of ifenprodil, the significant effect of blockade of the 5-HT1A
on its antidepressant activity was demonstrated (Poleszak
et al. 2014). In the case of traxoprodil (derivative of ifenprodil)
a similar effect was expected. It should be stressed that the
influence of above-mentioned substances on the activity of the
NMDA receptor ligands (e.g., MTEP, zinc, chromium) was
previously observed (Pałucha-Poniewiera et al. 2014;
Piotrowska et al. 2008; Szewczyk et al. 2009).
Due to a high probability of interaction between
traxoprodil and antidepressants in the pharmacokinetic phase,
the concentrations of the tested drugs in murine brain were
determined . Traxoprodil is metabolised by the system of cy-
tochrome P450 and influences the activity of izoenzyme
CYP2D6 (Johnson et al. 2003), which is engaged in the me-
tabolism of some antidepressants, e.g., imipramine, desipra-
mine, citalopram, fluoxetine, paroxetine or mianserin
(Pużyński 2005). When changes occur as a result of action
of antidepressant drugs but changes in the levels of these
drugs in blood and/or brain are not observed, it may be
suspected that the interaction occurs in the pharmacodynamic
phase (DeVane 2005). Pharmacodynamic interactions, as op-
posed to pharmacokinetic ones, do not alter drug concentra-
tions in blood and sites of drug action (DeVane et al. 2002).
Therefore, the data obtained in our studies suggested that
the interaction between traxoprodil and all tested antidepres-
sants have a pharmacokinetic character, insomuch as there
were significant changes in traxoprodil or tested agents
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concentrations in murine brain tissue. The increase in
antidepressant-like activity of imipramine observed in the
FST, was most likely to be the result of pharmacokinetic in-
teraction. It has been shown that traxoprodil significantly en-
hanced levels of imipramine (and its metabolite) in brains of
mice treated concomitantly with imipramine and traxoprodil.
In the case of fluoxetine it has been shown that its co-
administration with traxoprodil significantly enhances
traxoprodil concentration in brain tissue. This may indicate
that traxoprodil has an impact on imipramine metabolism
and facilitates imipramine/desipramine penetration to the
brain, leading to an augmentation in imipramine/
desipramine concentration in brain of experimental ani-
mals, while in the case of combined injection of
traxoprodil and escitalopram an increase in the mice brain
concentrations of both traxoprodil and escitalopram was
observed. These results suggest that the interaction
traxoprodil-escitalopram could have been pharmacokinetic
in nature. Because in the group of mice receiving
traxoprodil with reboxetine there was no shortening of
the immobility time of animals in the FST, reboxetine
concentrations in the brain of animals were not assessed.
Obviously, it could not be excluded that the observed
shortening of the immobility time in the FST after com-
bined administration of traxoprodil and tested drugs is also
a result of the interaction in the pharmacodynamic phase
(e.g., changes in the concentration of neurotransmitters or
receptor level in the CNS). Therefore, it is necessary to
expand research to analyse the nature of the occurring
interactions in more detail. Pharmacodynamic interactions
between traxoprodil and other antidepressant drugs are still
worth studying.
Summarizing the results of our research, it should be no-
ticed that selective antagonist of the NR2B subunit of the
NMDA receptor – traxoprodil at a dose 20 and 40 mg/kg,
exhibits antidepressant-like effect in the FST in mice. Co-
administration of traxoprodil with imipramine, fluoxetine or
escitalopram, each in subtherapeutic doses, significantly af-
fects the animals’ behavior in the FST and, what is important,
these changes are not due to the severity of locomotor activity
of animals. The observed effect of traxoprodil is only partially
associated with serotonergic system and is independent of the
effect on the 5-HT1A and 5-HT2 serotonin receptors. The re-
sults of an attempt to assess the nature of the interaction be-
tween traxoprodil and the tested drugs show that in the case of
joint administration of traxoprodil and fluoxetine, imipramine
or escitalopram, there are interactions in the pharmacokinetic
phase.
The obtained results suggest that the use of traxoprodil
together with antidepressants can allow us to lower the doses
of antidepressant agents and contribute to a more effective and
safer pharmacotherapy of patients suffering from affective
disorders.
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